Common immune signal in blood tests could help spot Alzheimer’s earlier – linking diagnosis, genetics and the future of longer brain health.
Alzheimer’s disease does not begin with memory loss. It begins years earlier, as silent biological changes accumulate in the brain long before symptoms surface. By the time a clinical diagnosis is made, neurodegeneration is often well underway – narrowing the window for meaningful intervention.
Despite advances in imaging and cerebrospinal fluid biomarkers, early detection remains expensive, invasive and unevenly accessible – a triple threat. As disease-modifying therapies inch forward, the field faces a pressing challenge: how to identify risk earlier and in routine care. A simple blood-based signal that reflects underlying brain pathology would represent a significant shift toward prevention-led cognitive longevity.
Against that backdrop, attention is turning to biomarkers that could be deployed at scale. A recent study published in Frontiers in Immunology highlights an unexpected contender – interferon-gamma (IFN-γ), a well-characterized immune signaling molecule long associated with inflammation and host defense [1]. While IFN-γ itself is not new, the strength of its association with Alzheimer’s disease is.
The researchers analyzed blood samples from 141 people – some diagnosed with Alzheimer’s, others with mild cognitive impairment and a group of healthy controls. They measured a panel of 16 inflammation-related proteins and compared them with cognitive test scores and genetic risk factors.
Among all the markers studied, IFN-γ stood out. Levels were highest in people with Alzheimer’s, lower in those with mild impairment, and lowest in healthy participants. On its own, IFN-γ was able to distinguish Alzheimer’s from healthy aging with impressive accuracy. When combined with basic clinical data and genetic information, the predictive power became even stronger.
A single immune signal in the blood carried a lot of information about who had Alzheimer’s and who didn’t.
The story becomes even more interesting when genetics comes into play. The APOE ε4 gene variant is the strongest known genetic risk factor for late-onset Alzheimer’s. Not everyone who carries it develops dementia, but it raises the odds significantly.
In this study, people with Alzheimer’s who carried APOE ε4 had the highest IFN-γ levels of all. Brain tissue data from other studies helped explain why. IFN-γ-related activity was especially strong in microglia, the brain’s immune cells, among APOE ε4 carriers.
Microglia are meant to protect the brain. In Alzheimer’s, however, they can become overactive, shifting into a harmful state that accelerates damage. The researchers found that IFN-γ appears to push microglia toward this unhealthy mode, especially in people with genetic vulnerability. Think of it as a volume knob: APOE ε4 turns the dial up, and IFN-γ amplifies the signal.
This matters for more than diagnosis alone. Earlier detection opens the door to earlier intervention, when the brain may still be resilient enough to respond. A simple blood marker like IFN-γ could eventually be used to monitor risk over time, track disease progression or even measure how well preventive strategies are working.
With this new blood biomarker, Alzheimer’s is partly becoming an immune-aging problem. Chronic, low-grade inflammation is a hallmark of aging itself. IFN-γ sits at the intersection of immunity, genetics and brain health, reinforcing the idea that extending lifespan without protecting cognitive health is not enough.
The researchers are careful not to overstate their findings. The study was conducted at a single center and offers a snapshot in time, not proof of cause and effect. It is still unclear whether IFN-γ in the blood directly drives brain changes or merely reflects what is happening within the brain.
Even so, the signal is strong enough to warrant attention. IFN-γ is easy to measure, widely studied and biologically plausible. With further validation, it could become part of a new generation of accessible tools that shift Alzheimer’s care from late-stage response to early-stage prevention.
[1] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1770509/full
